Cardiovascular side effects of antiobesity drugs: a yellow flag in the race to safe pharmacotherapy for obesity.
Mark
Allyn L
AL
D019440:Anti-Obesity Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism
D019440:Anti-Obesity Agents
Dev Cell. 2002 Apr;2(4):497-503
11970899
Cell. 1997 Jan 10;88(1):131-41
9019399
Dev Cell. 2002 Apr;2(4):489-95
11970898
Hypertension. 2002 Feb;39(2 Pt 2):496-501
11882597
Science. 1999 Mar 5;283(5407):1544-8
10066179
Cell. 2004 Jan 23;116(2):337-50
14744442
J Clin Invest. 1997 Jul 15;100(2):270-8
9218503
Am J Clin Nutr. 2009 Mar;89(3):973S-979S
19190071
N Engl J Med. 2009 Jan 1;360(1):44-52
19092146
Nat Med. 2004 Jul;10(7):734-8
15220914
Nat Neurosci. 2005 May;8(5):571-8
15856065
N Engl J Med. 2003 Mar 20;348(12):1085-95
12646665
Circulation. 2009 Sep 1;120(9):753-63
19687357
N Engl J Med. 1999 Sep 16;341(12):879-84
10486419
Lancet. 2007 Nov 17;370(9600):1706-13
18022033
Hypertension. 2006 Jul;48(1):58-64
16754792
N Engl J Med. 1997 Aug 28;337(9):629-30
9271487
Nat Med. 2004 Jul;10(7):739-43
15208705
Neurosci Lett. 1998 Jun 19;249(2-3):107-10
9682828
J Neurosci. 2003 Jul 9;23(14):5998-6004
12853417